{"title":"PD-1/PD-L1免疫治疗肝细胞癌的结构和时间动力学分析:历史、研究热点和新趋势","authors":"Talaiti Tuergan, Aimitaji Abulaiti, Yingmei Shao, Tuerganaili Aji","doi":"10.1080/21645515.2025.2540143","DOIUrl":null,"url":null,"abstract":"<p><p>This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the \"Timeline visualization of references,\" classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2540143"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363510/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.\",\"authors\":\"Talaiti Tuergan, Aimitaji Abulaiti, Yingmei Shao, Tuerganaili Aji\",\"doi\":\"10.1080/21645515.2025.2540143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the \\\"Timeline visualization of references,\\\" classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"21 1\",\"pages\":\"2540143\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363510/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2025.2540143\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2540143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
本研究旨在探讨近二十年来PD-1/PD-L1免疫治疗肝细胞癌(HCC)的历史演变、重点研究领域和新趋势,重点关注结构和时间动态。Web of Science Core Collection (WoSCC)数据库用于收集PD-1/PD-L1免疫治疗HCC的研究。利用CiteSpace和HistCite进行文献计量分析,探讨了该领域的历史进展、研究演变和新兴趋势。在过去的二十年中,已经发表了2804篇关于PD-1/PD-L1免疫治疗HCC的论文,包括541篇综述和来自2659个机构的13796位作者的贡献。自2014年以来,年度出版物数量显著增加,国际合作广泛。一些活跃的研究主题已经出现,涵盖72个学科,产生561个关键词,1199篇文章经历了引文爆发。关键词聚类分析揭示了五个新兴的子领域:lenvatinib、免疫逃逸、免疫检查点抑制剂、预后模型和肿瘤微环境。根据“参考文献的时间线可视化”,经典主题包括CMTM6、调节性T细胞、肝移植和生物信息学分析,而新兴主题包括预后、lenvatinib、经动脉化疗栓塞、肝动脉输注化疗和单细胞RNA测序。本研究揭示了PD-1/PD-L1免疫治疗肝癌的研究现状和发展趋势,为研究人员识别关键领域和探索新的研究方向提供了有价值的见解。
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.
This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the "Timeline visualization of references," classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.